What is NDC 81749-004?

81749-004 is the product NDC for Tarpeyo (budesonide), Budesonide 4 mg/1 capsule, delayed release, listed with the FDA by Calliditas Therapeutics AB. It has 1 package NDC, shown above in 10- and 11-digit form.

Calliditas Therapeutics AB, NDC labeler code 81749. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Tarpeyo?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Tarpeyo NDC 81749-004 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)81749-004Labeler and product segments. Claims need a package NDC.

Product NDC at billing width81749-0004Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
81749-004-01	8174900040181749000401	120 CAPSULE, DELAYED RELEASE in 1 BOTTLE (81749-004-01)Marketed from Dec 15, 2021

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Tarpeyo
Generic name (nonproprietary): budesonide
Active ingredients: Budesonide — 4 mg/1
Dosage form: Capsule, Delayed release
Route: Oral
Labeler: Calliditas Therapeutics ABNDC labeler code 81749
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 215935
Marketing start: Dec 15, 2021
Listing expires: Dec 31, 2027
Other FDA classes: Corticosteroid Hormone Receptor Agonists (Mechanism)
Identifiers: Product ID 81749-004_48e9b876-94c8-7c9f-e063-6294a90adcefSPL ID 48e9b876-94c8-7c9f-e063-6294a90adcefSPL set ID 938cada4-d6bf-4252-836f-dd40f9eadb4dRxCUI 2587883, 2587889UNII Q3OKS62Q6X
Pharmacologic class: Corticosteroid

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N481749000401 followed by a unit qualifier and the quantity

Package 81749-0004-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 21, 2026.

Indications (excerpt from the label)

TARPEYO is indicated to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression. TARPEYO is a corticosteroid indicated to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 81749-004

What is NDC 81749-004?: 81749-004 is the product NDC for Tarpeyo (budesonide), Budesonide 4 mg/1 capsule, delayed release, listed with the FDA by Calliditas Therapeutics AB. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Tarpeyo (Budesonide).
What is the active ingredient?: Budesonide.
Who is the labeler?: Calliditas Therapeutics AB, NDC labeler code 81749. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Tarpeyo?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Tarpeyo (Budesonide) NDC 81749-004